Epacadostat, nivolumab combination shows promise in certain advanced solid tumors

CHICAGO — Epacadostat in combination with nivolumab appeared safe and effective in patients with advanced melanoma and head and neck cancer, according to preliminary data from the ECHO-204 trial presented at the ASCO Annual Meeting.

Definitive Study Shows That People with Melanoma Do Not Need Immediate Lymph Node Removal

People with melanoma who test positive for cancer in their sentinel lymph node do not need to have their remaining regional lymph nodes immediately removed to improve their survival.

PDE-5 inhibitors and melanoma: No causal link found

Findings from a meta-analysis show that, while phosphodiesterase type 5 (PDE-5) inhibitor use is associated with a statistically significant increased risk of melanoma, they do not support a causal relationship, said lead author Stacy Loeb, MD, MSc, of NYU School of Medicine, New York.

Checkmate for Metastatic Brain Cancer

Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center are helping to make strides in the treatment of metastatic melanoma that has spread to the brain.

Cancer in the News

Feature Articles

FDA grants orphan drug designation to pIL-12 for unresectable melanoma

The FDA granted orphan drug designation to tavokinogene telsaplasmid for the treatment of unresectable metastatic melanoma, according to the agent’s manufacturer.

Read the full story

Posted in Melanoma In The News, FDA

Chemical Array Technique Promotes Stem Cell State to Identify Malignant Melanoma

Melanoma can be easily treated when caught early, but the real danger arises after the cancer has metastasized.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Dr. Ascierto on Triplet of Encorafenib, Binimetinib, and Ribociclib in Melanoma

Source: OncLive, June 2017 Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma. This is the […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

More Immuno Rx Strategies for Advanced Melanoma

Washington—Combining checkpoint inhibitors yields an overall survival (OS) benefit in advanced melanoma, according to Phase III data presented at the 2017 annual meeting of the American Association for Cancer Research (AACR).

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories